Cancer Drug Resistance
All Journals
Search
Log In
Editor-in-Chief:
Godefridus J. Peters
Indexing:
ESCI
,
PMC
,
Scopus
,
CAS
,
CNKI
,
Dimensions
,
Lens
,
Embase
,
Journal Rank:
Impact Factor 2023: 4.6 - Q1 (ONCOLOGY); CiteScore 2023: 6.6 - Q1 [Pharmacology(medical)]
Submission to first decision:
63 days
Journal Flyer
Hot Keywords
Resistance
Drug delivery
Nanomedicine
Tumor microenvironment
Immune checkpoint inhibitors
Target therapy
Immunotherapy
Radiotherapy
Ferroptosis
PARP inhibitors
MYC
ABC transporters
Autophagy
Metabolism
Mechanisms
Precision medicine
Extracellular vesicles
Stem cell
Biomarker
Ovarian cancer
Renal cell carcinoma
Prostate cancer
Breast cancer
Colorectal cancer
Myeloid leukemia
Non-small cell lung cancer
Pancreatic cancer
Head and neck cancer
Squamous cell carcinoma
Mitochondria
Home
About
About the Journal
Aims and Scope
Editorial Policies
Editorial Board
Junior Editorial Board
News
Journal History
Partners
Advertise
Contact Us
Publish with us
For Authors
Author Instructions
Article Processing Charges
Editorial Process
Manuscript Templates
Submit a Manuscript
For Reviewers
Peer Review Guidelines
Articles
All Articles
Articles with Video Abstracts
Video Abstract Guidelines
Articles Ebooks
Special Issues
All Special Issues
Ongoing Special Issues
Special Issue Ebooks
Special Issue Guidelines
Special Collections
Volumes
Pre-onlines
Features
Webinars
Academic Talks
Interviews
Home
Articles
Special Issues
Volumes
Webinars
Videos
Menu
Cancer Drug Resistance
Search
Submit
Editor-in-Chief:
Godefridus J. Peters
Journal Rank:
Impact Factor 2023: 4.6 - Q1 (ONCOLOGY); CiteScore 2023: 6.6 - Q1 [Pharmacology(medical)]
Submission to first decision:
63 days
Home
Articles
Special Issues
Volumes
Webinars
Videos
Menu
Home
Volumes
Volume6
Volume6, Issue2 (2023)
Volume
Targeting MYC-driven lymphoma: lessons learned and future directions
How acute myeloid leukemia (AML) escapes from FMS-related tyrosine kinase 3 (FLT3) inhibitors? Still an overrated complication?
Cancer stem cells in drug resistance: an introduction to the e-book covering the special issue on the “Cancer Stem Cells and Drug Resistance”
miR-16-5p enhances sensitivity to RG7388 through targeting <i>PPM1D</i> expression (WIP1) in Childhood Acute Lymphoblastic Leukemia
Review of 5-FU resistance mechanisms in colorectal cancer: clinical significance of attenuated on-target effects
Mitochondria in colorectal cancer stem cells - a target in drug resistance
Fungal mycobiome-mediated immune response: a non-negligible promoter in pancreatic oncogenesis and chemoresistance
Remodeling the tumor microenvironment to overcome treatment resistance in HPV-negative head and neck cancer
Revisiting mechanisms of resistance to immunotherapies in metastatic clear-cell renal-cell carcinoma
Major hurdles of immune-checkpoint inhibitors in pancreatic ductal adenocarcinoma
Importance of <i>ROS1</i> gene fusions in non-small cell lung cancer
The evolving role of DNA damage response in overcoming therapeutic resistance in ovarian cancer
Immune checkpoint inhibitors in ovarian cancer: where do we go from here?
Interaction of pregnane X receptor with hypoxia-inducible factor-1 regulates chemoresistance of prostate cancer cells
Recent advances in access to overcome cancer drug resistance by nanocarrier drug delivery system
Mechanisms and clinical implications in renal carcinoma resistance: narrative review of immune checkpoint inhibitors
Actions for 0 selected articles
Download PDFs >
Cancer Drug Resistance
ISSN 2578-532X (Online)
editorial@cdrjournal.com
Navigation
Contact Us
Sitemap
Follow Us
LinkedIn
Twitter
WeChat
Navigation
Contact Us
Sitemap
Committee on Publication Ethics
https://publicationethics.org/members/cancer-drug-resistance
Portico
All published articles will preserved here permanently:
https://www.portico.org/publishers/oae/
Committee on Publication Ethics
https://publicationethics.org/members/cancer-drug-resistance
Portico
All published articles will preserved here permanently:
https://www.portico.org/publishers/oae/